Fractyl Health Inc. Commo... (GUTS)
Company Description
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021.
The company was incorporated in 2010 and is based in Lexington, Massachusetts.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Dr. Harith Rajagopalan M.D., Ph.D. |
Contact Details
Address: 17 Hartwell Avenue Lexington, United States | |
| Website | https://fractyl.com |
Stock Details
| Ticker Symbol | GUTS |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001572616 |
| CUSIP Number | 35168W103 |
| ISIN Number | US35168W1036 |
| Employer ID | 27-3553477 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Harith Rajagopalan M.D., Ph.D. | Co-Founder, Chief Executive Officer & Director |
| Lisa A. Davidson MBA | Chief Financial Officer & Treasurer |
| Dr. Timothy J. Kieffer Ph.D. | Chief Scientific Officer |
| Jay D. Caplan BSEE, MBA | Co-Founder, Chief Product Officer & President |
| Jon Fitzgerald | Senior Vice President of Regulatory, Quality & Clinical |
| Sarah S. Toomey Esq. | General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Filing |
| Apr 24, 2025 | DEF 14A | Filing |
| Apr 23, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 01, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 4/A | [Amend] Filing |
| Mar 18, 2025 | 4 | Filing |
| Mar 18, 2025 | 4 | Filing |
| Mar 17, 2025 | 4 | Filing |
| Mar 17, 2025 | 4 | Filing |